Jingyu Deng

Jingyu Deng

Auto-generated profile, based on publicly available information

Jingyu Deng

Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2025 in BMJ Open
Verified
Journal Article
Open access
YLYidi Liang
Yidi Liang
XCXiaolong Chen
Xiaolong Chen
WZWeihan Zhang
Weihan Zhang
KYKun Yang
Kun Yang
XWXuefei Wang
Xuefei Wang
JHJian-Kun Hu
Jian-Kun Hu
Introduction: Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with most Chinese patients diagnosed at a locally advanced stage. Neoadjuvant chemotherapy (NAC) is increasingly used to improve resectability and survival. Laparoscopy-assisted distal gastrectomy (LADG) provides short-term recovery benefits compared with open distal gastrectomy (ODG), but its safety and oncologic efficacy following NAC remain uncertain. This trial aims to determine whether LADG is non-inferior to ODG in terms of long-term survival outcomes in patients with locally advanced distal gastric cancer (LAGC) after NAC. Methods and analysis: This is a multicentre, randomised, controlled, non-inferiority trial conducted at high-volume GC centres in China. Eligible patients (aged 18–75 years; cT3–4a, N0/+, M0) with histologically confirmed distal gastric adenocarcinoma who have completed standard NAC will be randomised 1:1 to LADG or ODG with D2 lymphadenectomy. Surgical quality will be standardised through operative manuals, intraoperative video recording and central auditing. The primary endpoint is 3-year disease-free survival. Secondary endpoints are 3- and 5-year overall survival. A total of 998 patients (499 per arm) will be enrolled, providing 80% power to test non-inferiority with an absolute 8% margin, accounting for 15% attrition. Analyses will follow the intention-to-treat principle, with Cox models used for survival comparisons and subgroup analyses according to nodal status, tumour size and pathological response. Ethics and dissemination: This trial has been reviewed and approved by the Biomedical Ethics Committee of West China Hospital, Sichuan University (Approval No. 2025 (865), 16 July 2025). Written informed consent will be obtained from all participants. The results will be disseminated through peer-reviewed journals and international conferences, providing high-level evidence to guide the surgical management of LAGC after NAC. Trial registration number: Chinese Clinical Trial Registry, ChiCTR2500109677; registered on 23 September 2025. Protocol V.2.1, dated 29 June 2025.

1 May 2026 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
XNXinyang Nie
Xinyang Nie
GLGang Li
Gang Li
ZLZhiqiang Liu
Zhiqiang Liu
BKBin Ke
Bin Ke
ZYZuli Yang
Zuli Yang
JDJingyu Deng
Jingyu Deng
Objective: This study aimed to propose and validate a new and practical lymph node (LN) staging strategy to mitigate staging migration due to examined LN (ELN) retrieval and improve the accuracy of prognostic evaluation for early gastric cancer (EGC) patients. Background: EGC patients often face staging inaccuracies due to inadequate ELNs, as there is no clear standard for ELN retrieval requirements. Methods: From an initial cohort of 7001 EGC patients across fifteen large institutions in China, 6566 eligible patients were included as the training and validation cohort after applying predefined exclusion criteria. We analyzed these data to determine the optimal cutoff value for the number of ELNs, construct a prediction model, and propose a new LN staging method distinct from that of the latest AJCC guidelines. Subsequently, 2094 patients (from 2326 with survival data available in the multicenter dataset) and 1944 patients (from 5262 initially retrieved from the SEER database after exclusions) were included as independent test cohorts to evaluate model performance, including the correlation between ELNs and metastatic LNs (MLNs) and survival differences. Results: This study found that ≤ 20 ELNs were inadequate for accurate LN evaluation in EGC patients. In the test cohort, MLNs was positively associated with ELNs. A model was constructed, and accurate MLNs could be displayed after correction for patients with inadequate ELNs. Survival analysis revealed significant differences between patients with different pNM (pN modified) stages in both the multicenter test cohort and the SEER test cohort. Conclusion: Model-corrected pNM staging may improve staging migration and survival prediction than the AJCC staging, showing great clinical applicability for EGC patients with ELN ≤ 20. A flowchart outlines a study on early gastric cancer patients, examining lymph nodes and metastasis risks.A study of 6566 early gastric cancer (EGC) patients across 15 Chinese centers determined the optimal examined lymph node (ELN) cutoff for lymph node metastasis (LNM) risk. Data was split into training and validation cohorts. A logistic regression model predicted LNM, correcting for insufficient ELNs and predicting metastatic lymph nodes (MLNs). 2094 multicenter and 1944 SEER EGC patients with survival data were tested. AJCC staging was redefined based on corrected ELNs/MLNs, grouped into PN stages and survival analysis was performed comparing pre- and post-correction differences.